Biogen Idec and UCB Enter Agreements to Commercialize Multiple Sclerosis ...

30-01-2014 Business WireComments (0)

Biogen IdecEisaiPharmaceutical

Biogen Idec (NASDAQ: BIIB) and UCB (Euronext: UCB) announced today that they have signed exclusive agreements granting UCB the right to commercialize Biogen Idec products in South ...

Read more on Business Wire

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top